inside the swiftly evolving area of cancer therapeutics, being familiar with the intricate mechanisms of Antibody-Drug Conjugates (ADCs) is important for developing helpful treatments. The most promising approaches is using in vitro bystander result assays, which play a pivotal function in improving therapeutic efficacy. These assays, supplied by c